Evidence map›Paper›PMID 32694617›Full record

ArticleLeukemia2021

Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study.

Sylvie Tondeur, Franciane Paul, Jérémie Riou, Olivier Mansier, Dana Ranta, Lenaïg Le Clech, Eric Lippert, Suzanne Tavitian, Driss Chaoui, Mélanie Mercier and 15 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. The Pyrosequencing-Based Method forDiagnostics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Diagnosis- and Prognosis-Related Gene Alterations inInternational journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Sylvie TondeurCHU Grenoble, Laboratoire de Génétique des hémopathies, Institut de Biologie et Pathologie, Grenoble, France.
Franciane PaulCHU Montpellier, Service d'Hématologie clinique, Montpellier, France.
Jérémie RiouUniversité d'Angers, INSERM 1066 MINT, Angers, France.
Olivier MansierCHU de Bordeaux, Laboratoire d'Hématologie et Université de Bordeaux, Inserm U1034, Bordeaux, France.
Dana RantaCHU Nancy, Hématologie clinique, Nancy, France.
Lenaïg Le ClechCH Quimper, Hématologie Clinique, Quimper, France.ORCID http://orcid.org/0000-0001-5586-9772
Eric LippertCHRU Brest, Laboratoire d'Hématologie, Brest, France.ORCID http://orcid.org/0000-0002-2312-6584
Suzanne TavitianCHU Toulouse, Service d'Hématologie, Toulouse Oncopole, Toulouse, France.
Driss ChaouiCH Argenteuil, Service d'Hématologie, Argenteuil, France.
Mélanie MercierCH Vannes, Hématologie clinique, Vannes, France.
Benoit De RenzisCHU Clermont-Ferrand, Hématologie clinique, Clermont-Ferrand, France.
Laurane CottinFédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.
Bruno CassinatAPHP, Hôpital Saint Louis, Laboratoire de Biologie Cellulaire, Paris, France.
Jean-Marie ChrétienCHU Angers, DRCI Cellule de Gestion des Données et Evaluation, Angers, France.
Jean-Christophe IanottoFédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.
Olivier AllangbaCH Saint-Brieuc, Hématologie Clinique, Brest, France.ORCID http://orcid.org/0000-0002-2876-4614
Christophe MarzacGustave Roussy, Département de Biologie et Pathologie médicales, Brest, France.
Laurent VoillatCentre Hospitalier William Morey, Chalon-sur-Saône, France.
Françoise BoyerFédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.
Corentin OrvainFédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.
Mathilde Hunault-BergerFédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.
François GirodonCHU Dijon, Service d'Hématologie Biologique, Dijon, France.
Jean-Jacques KiladjianAPHP, Hôpital Saint Louis, INSERM UMRS 1131, Institut Universitaire d'Hématologie, Paris, France.ORCID http://orcid.org/0000-0002-8121-438X
Valérie UgoFédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.
Damien Luque PazFédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France. damien.luquepaz@chu-angers.fr.ORCID http://orcid.org/0000-0002-4523-675X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ExonsMutationAdultAgedBiomarkers, TumorCohort StudiesFemaleFollow-Up StudiesFranceHumansJanus Kinase 2MaleMiddle AgedMyeloproliferative DisordersPolycythemia VeraPrognosisBiomarkers, TumorJAK2 protein, humanJanus Kinase 2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.